Rocket Pharmaceuticals, Inc. Operating Lease, Weighted Average Discount Rate, Percent
Rocket Pharmaceuticals, Inc. (RCKT) had Operating Lease, Weighted Average Discount Rate, Percent of 8.94% as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Leases
us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent · last filed 2026-08-10
- 2026-06-30: Operating Lease, Weighted Average Discount Rate, Percent 8.94%.
- 2026-03-31: Operating Lease, Weighted Average Discount Rate, Percent 8.93%.
- 2025-12-31: Operating Lease, Weighted Average Discount Rate, Percent 8.84%.
- 2025-09-30: Operating Lease, Weighted Average Discount Rate, Percent 8.83%.
| Period end | Operating Lease, Weighted Average Discount Rate, Percent | Operating Lease, Weighted Average Discount Rate, Percent as first filed |
|---|---|---|
| 2026-06-30 | 8.94% 10-Q · filed 2026-08-10 | |
| 2026-03-31 | 8.93% 10-Q · filed 2026-05-07 | |
| 2025-12-31 | 8.84% 10-K · filed 2026-02-26 | |
| 2025-09-30 | 8.83% 10-Q · filed 2025-11-06 | |
| 2025-06-30 | 8.83% 10-Q · filed 2026-08-10 | |
| 2025-03-31 | 8.82% 10-Q · filed 2026-05-07 | |
| 2024-12-31 | 8.82% 10-K · filed 2026-02-26 | |
| 2024-09-30 | 8.82% 10-Q · filed 2025-11-06 | |
| 2024-06-30 | 8.82% 10-Q · filed 2025-08-07 | |
| 2024-03-31 | 8.82% 10-Q · filed 2025-05-08 | |
| 2023-12-31 | 8.34% 10-K · filed 2025-02-27 | 8.32% 10-K · filed 2024-02-27 |
| 2023-09-30 | 8.34% 10-Q · filed 2024-11-07 | |
| 2023-06-30 | 8.25% 10-Q · filed 2024-08-06 | |
| 2023-03-31 | 8.08% 10-Q · filed 2024-05-07 | |
| 2022-12-31 | 6.44% 10-K · filed 2025-02-27 | |
| 2022-09-30 | 3.94% 10-Q · filed 2022-11-04 | |
| 2022-06-30 | 4.17% 10-Q · filed 2022-08-09 | |
| 2022-03-31 | 4.34% 10-Q · filed 2022-05-06 | |
| 2021-12-31 | 4.46% 10-K · filed 2024-02-27 | |
| 2021-09-30 | 4.67% 10-Q · filed 2021-11-05 | |
| 2021-06-30 | 4.75% 10-Q · filed 2021-08-09 | |
| 2021-03-31 | 4.90% 10-Q · filed 2021-05-10 | |
| 2020-12-31 | 7.77% 10-K · filed 2021-03-01 | |
| 2020-09-30 | 7.77% 10-Q · filed 2020-11-06 | |
| 2020-06-30 | 7.77% 10-Q · filed 2020-08-05 | |
| 2020-03-31 | 7.77% 10-Q · filed 2020-05-08 | |
| 2019-12-31 | 7.77% 10-K · filed 2020-03-06 | |
| 2019-09-30 | 7.77% 10-Q · filed 2019-11-08 | |
| 2019-06-30 | 7.77% 10-Q · filed 2019-08-08 | |
| 2019-03-31 | 7.77% 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |